AI specialist Quinten Health bags €14m financing

The financing is part of the Quinten Group's €14m growth equity investment from Techlife Capital and MACSF, dedicated to the healthcare activities of the company. Paris-based Quinten Health pioneers solutions in real-world data science, artificial intelligence (AI) and machine learning (ML) such as advanced statistical modeling, patterns recognition and subgroups discovery for predictive medicine and patient simulation.

The company wants to use the proceeds to advance its in silico disease and care simulation platform into regulatory-grade disease cohort simulators to accelerate, de-risk and maximize the value of pharmaceutical R&D. Quinten Health intends to announce trategic partnerships with Big Pharma companies and data owners in the coming months to launch the first disease modeling platforms.

"Our disease models leverage from the leading data networks/platforms and combine the best from AI/ML, predictive modeling, and pharmaco-epidemiology. We are building reference ‘virtual twin’ simulators in high priority diseases to accelerate drug development and patient access to the drugs they really need", said Dr Billy Amzal, CEO of Quinten Health. "Our disease models will drastically reduce time to insights for drug developers, learning over time and across data sources on the disease and care continuum", priomised Dr Alexandre Templier, President of the Quinten group.